Quest Diagnostics (DGX) maintains a strong position in the diagnostics market, demonstrating positive growth through
Q3 2025. The company has surpassed earnings and revenue estimates, and its stock value has increased by 2.6% since the last earnings report. This strong financial performance is driven by prudent decisions like the completion of the
acquisition of clinical testing assets from Fresenius Medical Care and launching new testing for the Oropouche Virus. The company continues to innovate with introductions like advanced pharmacogenomics offering and Alzheimer's blood testing. Its partnership with Epic, Google Cloud, and others showcases a commitment to improving laboratory testing experience and leveraging AI for data streamlining. It's MD Anderson Technology-based MCaST blood test development and FDA-approved collaboration with Guardant Health exemplify groundbreaking stridings. Coupling with the raised financial guidance for
2025 predicts continued growth. However, DGX acknowledges potential risks in tariff and Medicare Act. The results, along with analyst endorsements, have strengthened DGX's position as a top-ranked value and growth stock.
Quest Diagnostics DGX News Analytics from Thu, 30 Jan 2025 08:00:00 GMT to Sun, 23 Nov 2025 00:36:02 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 1
